Myelodyspastics Syndrome (MDS) Prognosis: Risk Scoring Systems

It is not possible to give a precise outcome for you as an individual patient but this scoring system is useful for a discussion about the future and the options for treatment that may help.

As research, understanding and information about MDS is constantly evolving and improving, the data gathered enables clinicians to categorise sub-types of MDS even more precisely.

First, the basic IPSS was developed with 4 MDS risk categories: Low risk, Intermediate 1, Intermediate 2, High-risk

Then, in 2013, it was improved to the IPSS-R, which has been the standard since 2015-2016 and consists of 5 categories: Very low-risk, Low-risk, Intermediate, High-risk, Very high-risk.

Within the next 2 years - around late 2017 or 2018 -  we are expecting the IPSS-Mol. This will take into account research and results on MDS gene mutations and provide a further layer of details, possibly telling us which patients may respond better to specific treatments, or for whom a transplant should be attempted earlier – or perhaps avoided all together.

It is hoped the IPSS-Mol may reduce the difficult uncertainty factor a little further – which would be another important step forward in MDS care.

Understanding MDS Patient Handbook

This booklet has been written to help you understand more about MDS. Download it and learn more about MDS and what the prognosis of MDS is in Chapter 6.

Download PDF

Revised International Prognostic Scoring System (IPSS-R)

Learn more about the IPSS-R, developed in 2013, which has been the new standard since 2015-2016

Go to site

Myelodysplastic Syndromes by Austin Kulasekararaj

Download this presentation and learn more about MDS and the risk associated with each MDS type.

Download PDF

Using DNA Mutations in MDS to Guide Treatment

Latest research updated in Feb 2016 with an in-depth analysis of the genes that have been identified as affecting survival.


Go to site

Myelodysplastic Syndromes, Part 2, by Dr Austin Kulasekararaj

Download this presentation and learn more about how long it takes to diagnose MDS, the risk scoring of the different types of MDS and much more.

Download PDF

High Risk MDS and Hypomethylating Agents, by Dr Kavita Raj

An in-depth presentation which describes clearly how to determine the best treatment options for High Risk MDS patients.

Download PDF

Free donations by shopping